Enable Injections and Swedish Orphan Biovitrum (Sobi) have signed a global development and distribution deal for Aspaveli (pegcetacoplan) with enFuse Injector combination.
Enable Injections is known for its enFuse wearable drug delivery platform, whereas Sobi is a rare disease-focused biotechnology firm.
Under the collaboration, the enFuse Injector will be developed for the subcutaneous delivery of Aspaveli.
Aspaveli /Empaveli is a targeted C3 therapy that regulates excessive complement cascade activation, a part of the immune system.
The therapy is approved for treating paroxysmal nocturnal haemoglobinuria (PNH) in the US, European Union, and other countries.
It is also being investigated for several rare diseases in haematology and nephrology.
Sobi and Apellis share global co-development rights for systemic pegcetacoplan.
The Swedish firm holds exclusive commercialisation rights outside the US, while Apellis has exclusive US commercialisation rights for systemic pegcetacoplan and worldwide rights for ophthalmological pegcetacoplan, including for geographic atrophy.
Created by Enable and distributed by Sobi, the enFuse Injector is designed to enhance patient self-administration with minimal disruption.
This wearable device uses enFuse technology to deliver medication through a discreet, hidden needle with an under-the-skin injection.
Enable Injections chairman and CEO Michael Hooven said: “The future availability of Aspaveli with Enable Injection’s enFuse technology, could offer more patients the opportunity to access a simplified treatment experience that allows for greater confidence and mobility.
“Enable was founded on the goal of redefining drug delivery for the benefit of patients, and our partnership with Sobi is helping us achieve that.”
Enable Injections is collaborating with several pharmaceutical partners on clinical trials and planning for joint commercial launches using enFuse technology.
The first enFuse combination product received US Food and Drug Administration (FDA) approval in October 2023.
Sobi chief medical officer and medical affairs, R&D head Lydia Abad-Franch said: “We are dedicated to advancing innovative solutions for the treatment of rare diseases, and this agreement with Enable Injections marks an important step in fulfilling that commitment.
“We believe the agreement with Enable will potentially expand patient choice, enhance comfort and support adherence, with the ultimate aim of better health outcomes.”
